MDACC Study No:GOG 0241 ( NCT No: NCT01081262)
Title:A GCIG Intergroup Multicenter Phase III Trial of Open Label Carboplatin and Paclitaxel +/- NCI Supplied Agent: Bevacizumab (NSC #704865, IND #113912) Compared with Oxaliplatin and Capecitabine +/- Bevacizumab as First Line Chemotherapy in Patients with Mucinous Epithelial Ovarian or Fallopian Tube Cancer (MEOC)
Principal Investigator:Michael M. Frumovitz
Treatment Agent:Bevacizumab; Capecitabine; Carboplatin; Oxaliplatin; Paclitaxel
Study Status:Closed
Study Description:The goal of this clinical research study is to compare several different study
drug combinations to learn if and how well the study treatments may help to
control mucinous adenocarcinoma of the ovary or fallopian tube. Oxaliplatin,
capecitabine, paclitaxel, and bevacizumab will be studied in different

Researchers want to learn if the combination of capecitabine and oxaliplatin
with or without bevacizumab may work better to help control the disease
compared to standard treatment with paclitaxel and carboplatin. The safety of
the study treatments will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Fallopian Tube; Ovary
Phase of Study:Phase III
Treatment Agents:Bevacizumab
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Genentech
Gynecologic Oncology Group
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Michael M. Frumovitz
Dept:Gynecologic Oncology
For Clinical Trial Enrollment:713-792-9599
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults